2 weeks Ago By ABMN Staff
Geode Capital Management LLC increased its holdings in Sage Therapeutics, Inc. ( NASDAQ:SAGE – Free Report ) by 1.1% during the fourth quarter, Holdings Channel.
com reports. The firm owned 1,256,903 shares of the biopharmaceutical company’s stock after acquiring an additional 14,049 shares during the quarter. Geode Capital Management LLC’s holdings in Sage Therapeutics were worth $6,827,000 at the end of the most recent quarter.
Several other hedge funds have also added to or reduced their stakes in SAGE. Picton Mahoney Asset Management increased its holdings in shares of Sage Therapeutics by 126.0% in the fourth quarter.
Picton Mahoney Asset Management now owns 6,423 shares of the biopharmaceutical company’s stock worth $35,000 after buying an additional 3,581 shares during the period. KLP Kapitalforvaltning AS bought a new position in Sage Therapeutics during the 4th quarter worth approximately $49,000. Ieq Capital LLC purchased a new position in Sage Therapeutics in the 4th quarter worth approximately $57,000.
US Bancorp DE lifted its position in Sage Therapeutics by 22.3% in the fourth quarter. US Bancorp DE now owns 12,430 shares of the biopharmaceutical company’s stock valued at $67,000 after purchasing an additional 2,268 shares during the last quarter.
Finally, Teacher Retirement System of Texas boosted its stake in shares of Sage Therapeutics by 21.6% during the fourth quarter. Teacher Retirement System of Texas now owns 13,768 shares of the biopharmaceutical company’s stock valued at $75,000 after purchasing an additional 2,446 shares during the period.
99.22% of the stock is owned by institutional investors. Wall Street Analyst Weigh In Several brokerages recently commented on SAGE.
Needham & Company LLC reaffirmed a “hold” rating on shares of Sage Therapeutics in a research note on Wednesday, February 12th. Bank of America initiated coverage on shares of Sage Therapeutics in a research note on Tuesday, March 11th. They set an “underperform” rating and a $5.
00 price objective for the company. Scotiabank reduced their price target on Sage Therapeutics from $14.00 to $12.
00 and set a “sector outperform” rating on the stock in a report on Wednesday, February 12th. Canaccord Genuity Group dropped their price objective on Sage Therapeutics from $9.00 to $8.
00 and set a “hold” rating for the company in a report on Wednesday, February 12th. Finally, HC Wainwright reiterated a “neutral” rating and issued a $12.00 price objective (down from $14.
00) on shares of Sage Therapeutics in a research report on Wednesday, February 12th. Three equities research analysts have rated the stock with a sell rating, fifteen have assigned a hold rating and two have assigned a buy rating to the company’s stock. According to data from MarketBeat, Sage Therapeutics presently has an average rating of “Hold” and an average target price of $8.
81. Sage Therapeutics Trading Up 2.2 % SAGE stock opened at $7.
79 on Friday. The stock’s 50 day simple moving average is $7.51 and its 200 day simple moving average is $6.
74. Sage Therapeutics, Inc. has a 12-month low of $4.
62 and a 12-month high of $14.97. The stock has a market capitalization of $478.
94 million, a PE ratio of -1.18 and a beta of 0.48.
Sage Therapeutics ( NASDAQ:SAGE – Get Free Report ) last announced its quarterly earnings results on Tuesday, February 11th. The biopharmaceutical company reported ($1.56) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.
54) by ($0.02). Sage Therapeutics had a negative net margin of 971.
50% and a negative return on equity of 68.18%. On average, research analysts predict that Sage Therapeutics, Inc.
will post -3.52 earnings per share for the current year. Sage Therapeutics Company Profile ( Free Report ) Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines.
Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression. Recommended Stories Want to see what other hedge funds are holding SAGE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sage Therapeutics, Inc.
( NASDAQ:SAGE – Free Report ). Receive News & Ratings for Sage Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sage Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter .
.
